The effect of antidepressant warnings on prescribing trends in Ontario, Canada

American Journal of Public Health

Volumn 97, Issue 4, 2007, Pages 750-754

  Kurdyak, Paul A ^a,b   Juurlink, David N ^b   Mamdani, Muhammad M ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CANADA; CONTROLLED STUDY; DRUG EFFECT; GROUPS BY AGE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRESCRIPTION; SUICIDAL BEHAVIOR; UNITED KINGDOM; ADOLESCENT; AGE; CHILD; CLINICAL PRACTICE; FEMALE; MALE; MIDDLE AGED; PACKAGING; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS; SUICIDE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; ONTARIO; PAROXETINE; PHYSICIAN'S PRACTICE PATTERNS; PRODUCT LABELING; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SUICIDE;

EID: 33947496346     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.2006.087262     Document Type: Article

References (19)

1. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990;147:207-210.
2. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160:790-792.
3. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292: 338-343.
4. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330:396-399.
5. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry. 2005;62: 165-172.
6. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163:41-47.
7. Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry. 2006; 163:813-821.
8. Duff G. Safety of Seroxat (Paroxetine) in children and adolescents under 18 years - contraindication in the treatment of depressive illness. London, England: Committee on Safety of Medicines; 2003. Available from: http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dID= 2491&noSaveAs=0&Rendition=WEB. Accessed: November 3, 2004.
9. US Food and Drug Administration. FDA issues public health advisory entitled: Reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). Rockville, Md: US Food and Drug Administration, Department of Health and Human Services; 2003.
10. US Food and Drug Administration. Suicidality in children and adolescents being treated with antidepressant medications. Rockville, Md: US Food and Drug Administration, Center for Drug Evaluation and Research; 2004.
11. Waechter F. Paroxetine must not be given to patients under 18. BMJ. 2003;326:1282.
12. US Food and Drug Administration. Worsening depression and suicidality in patients being treated with antidepressant medications. Rockville, Md: US Food and Drug Administration, Center for Drug Evaluation and Research; 2004.
13. Health Canada. Health Canada advises Canadians of stronger warnings for SSRIs and other newer anti-depressants. Ottawa, Ontario: Health Canada; 2004. Available from: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2004/ 2004_31_e.html. Accessed November 3, 2004.
14. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351:543-551.
15. Tu K, Mamdani MM, Jacka RM, Forde NJ, Rothwell DM, Tu JV. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ. 2003;168:553-557.
16. Helfenstein U. Box-Jenkins modelling in medical research. Stat Methods Med Res. 1996;5:3-22.
17. Ljung G, Box G. On a measure of lack of fit in time series models. Biometrika. 1978; 67:297-303.
18. Lasser KE, Seger DL, Yu DT, et al. Adherence to black box warnings for prescription medications in outpatients. Arch Intern Med. 2006;166:338-344.
19. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215-2220.